Cited by 2,604Heart Failure Treatment and ManagementRenin-Angiotensin System StudiesHeart rate and cardiovascular health

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

McMurray, John JV, Östergren, Jan, Swedberg, Karl, Granger, Christopher B, Held, Peter, Michelson, Eric L, Olofsson, Bertil, Yusuf, Salim, Pfeffer, Marc A·2003·The Lancet

DOI 10.1016/s0140-6736(03)14283-3

Open this paper in CoChat — free account

Abstract

Background Angiotensin II type 1 receptor blockers have favourable effects on haemodynamic measurements, neurohumoral activity, and left-ventricular remodelling when added to angiotensin-converting-enzyme (ACE) inhibitors in patients with chronic heart failure (CHF). We aimed to find out whether these drugs improve clinical outcome.Methods Between March, 1999, and November, 1999, we enrolled 2548 patients with New York Heart Association functional class II-IV CHF and left-ventricular ejection fraction 40% or lower, and who were being treated with ACE inhibitors. We randomly assigned patients candesartan (n=1276, target dose 32 mg once daily) or placebo (n=1272). At baseline, 55% of patients were also treated with beta blockers and 17% with spironolactone. The primary outcome of the study was the composite of cardiovascular death or hospital admission for CHF. Analysis was done by intention to treat.Findings The median follow-up was 41 months. 483 (38%) patients in the candesartan group and 538 (42%) in the placebo group experienced the primary outcome (unadjusted hazard ratio 0.85 [95% CI 0.75-0.96], p=0.011; covariate adjusted p=0.010). Candesartan reduced each of the components of the primary outcome significantly, as well as the total number of hospital admissions for CHF. The benefits of candesartan were similar in all predefined subgroups, including patients receiving baseline beta blocker treatment.Interpretation The addition of candesartan to ACE inhibitor and other treatment leads to a further clinically important reduction in relevant cardiovascular events in patients with CHF and reduced left-ventricular ejection fraction.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(03)14283-3

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure
Garg, R. (1995) · JAMA · doi:10.1001/jama.273.18.1450 · Cited by 1,993
ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary
Hunt, S. A., Baker, D. W., Chin, M. H., Cinquegrani, M. P., Feldman, A. M., Francis, G. S., Ganiats, T. G., Goldstein, S., Gregoratos, G., Jessup, M. L., et al. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01683-7 · Cited by 1,909
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme
Pfeffer, M. A., Swedberg, K. B., Granger, C. B., Held, P., McMurray, J. J. V., Michelson, E. L., Olofsson, B., Östergren, J., & Yusuf, S. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14282-1 · Cited by 1,895
Self-citation
Guidelines for the diagnosis and treatment of chronic heart failure
Remme, W. J. (2001) · European Heart Journal · doi:10.1053/euhj.2001.2783 · Cited by 1,595
Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients
Flather, M. D., Yusuf, S., Køber, L., Pfeffer, M. A., Hall, A. S., Murray, G. D., Torp-Pedersen, C. T., Ball, S. G., Pogue, J. M., Moyé, L. A., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02212-1 · Cited by 1,585
Self-citation
The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosis
Cleland, J. G. F. (2003) · European Heart Journal · doi:10.1016/s0195-668x(02)00823-0 · Cited by 1,553
ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure)
Hunt, S. A., Baker, D. W., Chin, M. H., Cinquegrani, M. P., Feldman, A. M., Francis, G. S., Ganiats, T. G., Goldstein, S., Gregoratos, G., Jessup, M. L., et al. (2001) · Circulation · doi:10.1161/hc4901.102568 · Cited by 1,440
Effect of Amlodipine on Morbidity and Mortality in Severe Chronic Heart Failure
Packer, M., O’Connor, C. M., Ghali, J. K., Pressler, M. L., Carson, P. E., Belkin, R. N., Miller, A. B., Neuberg, G. W., Frid, D. J., WERTHEIMER, J. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610103351504 · Cited by 1,194

Show all 38 references

Sorted by citations

Items 601–700 of 1,001

Mega clinical trials which have shaped the RAS intervention clinical practice
Düsing, R. (2016) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944716644131 · Cited by 44
Drug Therapy for Stable Angina Pectoris
Rousan, T. A., Mathew, S. T., & Thadani, U. (2017) · Drugs · doi:10.1007/s40265-017-0691-7 · Cited by 46
Epidemiología de la hiperpotasemia en la enfermedad renal crónica
Belmar, L., Galabia, E. R., da Silva, J. B., González, M. B., Fresnedo, G. F., Haces, C. P., Fontanet, R. P., Ruiz, J. C., & de Francisco, Á. L. M. (2019) · Nefrología · doi:10.1016/j.nefro.2018.11.011 · Cited by 43
Epidemiology of hyperkalemia in chronic kidney disease
Belmar, L., Galabia, E. R., da Silva, J. B., González, M. B., Fresnedo, G. F., Haces, C. P., Fontanet, R. P., Ruiz, J. C., & de Francisco, Á. L. M. (2019) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2018.11.014 · Cited by 43
Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction
Liu, B., Wang, Y., Zhang, Y., & Yan, B. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190828161409 · Cited by 43
Cost-Effectiveness of the International Late Effects of Childhood Cancer Guideline Harmonization Group Screening Guidelines to Prevent Heart Failure in Survivors of Childhood Cancer
Ehrhardt, M. J., Ward, Z. J., Liu, Q., Chaudhry, A. B., Nohria, A., Border, W. L., Fulbright, J. M., Mulrooney, D. A., Oeffinger, K. C., Nathan, P. C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00418 · Cited by 45
Exploring the potential of telmisartan in chronic constriction injury-induced neuropathic pain in rats
Jaggi, A. S., & Singh, N. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.06.017 · Cited by 43
Radionuclide Imaging of Angiotensin II Type 1 Receptor Upregulation After Myocardial Ischemia–Reperfusion Injury
Higuchi, T., Fukushima, K., Xia, J., Mathews, W. B., Läutamaki, R., Bravo, P. E., Javadi, M. S., Dannals, R. F., Szabó, Z. R., & Bengel, F. M. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.079855 · Cited by 43
Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis
Chrysant, S. G., Murray, A. V., Hoppe, U. C., Dattani, D., PATEL, S. N., Hsu, H., & Zhang, J. Y. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x280581 · Cited by 43
The death rate among hospitalized heart failure patients with normal and depressed left ventricular ejection fraction in the year following discharge: evolution over a 10-year period
Shamagian, L. G., González‐Juanatey, J. R., Roman, A. V., García‐Acuña, J. M., & Lamela, A. V. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi383 · Cited by 43
Treatment of chronic heart failure: a comparison between the major guidelines
McMurray, J. J. V. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl123 · Cited by 43
Self-citation
ACE Inhibitors in Cardiovascular Disease — Unbeatable?
McMurray, J. J. V. (2008) · New England Journal of Medicine · doi:10.1056/nejme0801925 · Cited by 43
Self-citation
The Divergent Cardiovascular Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Myocardial Infarction and Death
Strauss, M. H., & Hall, A. S. (2015) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2015.11.004 · Cited by 43
Redesign of a short-chain dehydrogenase/reductase for asymmetric synthesis of ethyl (R)-2-hydroxy-4-phenylbutanoate based on per-residue free energy decomposition and sequence conservatism analysis
Su, B., Xu, L., Xu, X., Wang, L., Li, A., Lin, J., Ye, L., & Yu, H. (2020) · Green Synthesis and Catalysis · doi:10.1016/j.gresc.2020.09.003 · Cited by 42
Adverse Drug Reactions in Patients with Cardiovascular Disease
Faulx, M. D., & Francis, G. S. (2008) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2008.08.002 · Cited by 42
Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination
Cagnoni, F. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s11816 · Cited by 42
Management of Heart Failure Patients with Reduced Ejection Fraction
Mann, D. L. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0398-6.00028-7 · Cited by 42
The Role of Angiotensin II Type 1 Receptor Antagonists in Elderly Patients with Hypertension
Thomas, G. N., Chan, P., & Tomlinson, B. (2006) · Drugs & Aging · doi:10.2165/00002512-200623020-00004 · Cited by 42
Angiotensin in atherosclerosis
Kon, V., & Jabs, K. L. (2004) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-200405000-00005 · Cited by 42
Treatment strategies in patients with chronic renal disease: ACE inhibitors, angiotensin receptor antagonists, or both?
Hilgers, K., D�tsch, J., Rascher, W., & Mann, J. E. (2004) · Pediatric Nephrology · doi:10.1007/s00467-004-1554-5 · Cited by 42
Efficacy and Safety of Sodium–Glucose Co-Transporter 2 Inhibition According to Left Ventricular Ejection Fraction in DAPA-HF
Dewan, P., Solomon, S. D., Jhund, P. S., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., DeMets, D. L., Sabatine, M. S., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1867 · Cited by 41
Self-citation
Angiotensin Receptor Blockers and Outcomes in Real-World Older Patients with Heart Failure and Preserved Ejection Fraction: A Propensity-Matched Inception Cohort Clinical Effectiveness Study
Patel, K., Fonarow, G. C., Kitzman, D. W., Aban, I., Love, T. E., Allman, R. M., Gheorghiade, M., & Ahmed, A. (2012) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs101 · Cited by 41
Dual inhibition of the renin system by aliskiren and valsartan
Birkenhäger, W. H., & Staessen, J. A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61099-x · Cited by 41
Renin Activity in Heart Failure with Reduced Systolic Function—New Insights
Sullivan, R. D., Mehta, R. M., Tripathi, R., Reed, G. L., & Gladysheva, I. P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133182 · Cited by 42
Optimal Antagonism of the Renin-Angiotensin-Aldosterone System
Werner, C. M., Pöss, J., & Böhm, M. (2010) · Drugs · doi:10.2165/11537910-000000000-00000 · Cited by 41
Angiotensin II Receptor Antagonists Alone and Combined with Hydrochlorothiazide
Meredith, P. (2005) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200505030-00004 · Cited by 41
Effects of AGTR1 A1166C Gene Polymorphism in Patients with Heart Failure Treated with Candesartan
de Denus, S., Zakrzewski‐Jakubiak, M., Dubé, M., Bélanger, F., Lepage, S., Leblanc, M.-H., Gossard, D., Ducharme, A., Racine, N., Whittom, L., et al. (2008) · Annals of Pharmacotherapy · doi:10.1345/aph.1k657 · Cited by 41
Implications of Recently Published Trials of Blood Pressure–Lowering Drugs in Hypertensive or High-Risk Patients
Staessen, J. A., Richart, T., Wang, Z., & Thijs, L. (2010) · Hypertension · doi:10.1161/hypertensionaha.108.122879 · Cited by 41
Potential mechanisms of beneficial effect of sacubitril/valsartan on glycemic control
Seferović, J. P., Solomon, S. D., & Seely, E. W. (2020) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820970444 · Cited by 41
Angiotensin Receptor Neprilysin Inhibition in Heart Failure: Mechanistic Action and Clinical Impact
Buggey, J., Mentz, R. J., DeVore, A. D., & Velazquez, E. J. (2015) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2015.07.008 · Cited by 40
Association of Outcome with Left Ventricular Parameters Measured by Two-Dimensional and Three-Dimensional Echocardiography in Patients at High Cardiovascular Risk
Stanton, T., Jenkins, C., Haluska, B. A., & Marwick, T. H. (2013) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2013.09.012 · Cited by 40
Administration of antioxidant peptide SS-31 attenuates transverse aortic constriction-induced pulmonary arterial hypertension in mice
Lu, H., Huang, T., Sung, P., Chen, Y., Chua, S. O., Chai, H.-Y., Chung, S., Liu, C.-F., Sun, C., Chang, H., et al. (2016) · Acta Pharmacologica Sinica · doi:10.1038/aps.2015.162 · Cited by 41
Neprilysin Inhibitor–Angiotensin II Receptor Blocker Combination Therapy (Sacubitril/valsartan) Suppresses Atherosclerotic Plaque Formation and Inhibits Inflammation in Apolipoprotein E- Deficient Mice
Zhang, H., Liu, G., Zhou, W., Zhang, W., Wang, K., & Zhang, J. (2019) · Scientific Reports · doi:10.1038/s41598-019-42994-1 · Cited by 43
Quality of life and outcomes in heart failure patients with ejection fractions in different ranges
Chen, X., Xin, Y., Hu, W., Zhao, Y., Zhang, Z., & Zhou, Y. (2019) · PLoS ONE · doi:10.1371/journal.pone.0218983 · Cited by 40
Cancer Mortality in Trials of Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta‐Analysis
Tini, G., Bertero, E., Signori, A., Sormani, M. P., Maack, C., de Boer, R. A., Canepa, M., & Ameri, P. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.016309 · Cited by 40
Chronic Obstructive Pulmonary Disease, Risk Factors, and Outcome Trials: Comparisons with Cardiovascular Disease
Ramsey, S. D., & Hobbs, R. F. (2006) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200603-094ss · Cited by 41
Management of end stage cardiac failure
Johnson, M. J. (2007) · Postgraduate Medical Journal · doi:10.1136/pgmj.2006.055723 · Cited by 40
Effects of Optimized Heart Failure Therapy and Anemia Correction with Epoetin β on Left Ventricular Mass in Hemodialysis Patients
Hampl, H., Hennig, L., Rosenberger, C., Amirkhalily, M., Gogoll, L., Riedel, E., & Scherhag, A. W. (2005) · American Journal of Nephrology · doi:10.1159/000085881 · Cited by 40
The Impact of Extra Cardiac Comorbidities on Pressure Volume Relations in Heart Failure and Preserved Ejection Fraction
Abramov, D., He, K., Wang, J., Burkhoff, D., & Maurer, M. S. (2011) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2011.03.010 · Cited by 40
Heart Failure in Women: Epidemiology, Biology and Treatment
Shah, R. U., Klein, L., & Lloyd‐Jones, D. M. (2009) · Women s Health · doi:10.2217/whe.09.50 · Cited by 42
EXPERT CONSENSUS DOCUMENT ON ANGIOTENSIN CONVERTING ENZYME INHIBITORS IN CARDIOVASCULAR DISEASE
Lopez-Sendon, J., Swedberg, K. B., McMurray, J. J. V., Tamargo, J. L., Maggioni, A. P., Dargie, H., Tendera, M., Waagstein, F., Kjekshus, J., Lechat, P. P., et al. (2005) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2005-1-1-49-69 · Cited by 40
Self-citation
Rationale and Design of a Randomized Trial to Assess the Effects of β-blocker in Diastolic Heart Failure; Japanese Diastolic Heart Failure Study (J-DHF)
Hori, M., Kitabatake, A., Tsutsui, H., Okamoto, H., Shirato, K., Nagai, R., Izumi, T., Yokoyama, H., Yasumura, Y., Ishida, Y., et al. (2005) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2005.04.003 · Cited by 40
Polypharmacy in Older Heart Failure Patients: a Multidisciplinary Approach
Sukumar, S., Orkaby, A. R., Schwartz, J. B., Marcum, Z. A., Januzzi, J. L., Vaduganathan, M., & Warraich, H. J. (2022) · Current Heart Failure Reports · doi:10.1007/s11897-022-00559-w · Cited by 40
Meta-Analysis of Large-Scale Randomized Trials to Determine the Effectiveness of Inhibition of the Renin-Angiotensin Aldosterone System in Heart Failure
Emdin, C. A., Callender, T., Cao, J., McMurray, J. J. V., & Rahimi, K. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.03.052 · Cited by 39
Self-citation
Aliskiren: review of efficacy and safety data with focus on past and recent clinical trials
Şen, S., Sabırlı, S., Özyiğit, T., & Üresin, Y. (2013) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622313495288 · Cited by 39
Neprilysin Inhibition in Heart Failure with Reduced Ejection Fraction: A Clinical Review
King, J. B., Bress, A. P., Reese, A. D., & Munger, M. A. (2015) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1629 · Cited by 43
Novel Cardiac Intracrine Mechanisms Based on Ang-(1-12)/Chymase Axis Require a Revision of Therapeutic Approaches in Human Heart Disease
Reyes, S., Varagić, J., Ahmad, S., VonCannon, J. L., Kon, N. D., Wang, H., Groban, L., Cheng, C. P., Dell’Italia, L. J., & Ferrario, C. M. (2017) · Current Hypertension Reports · doi:10.1007/s11906-017-0708-3 · Cited by 39
From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5)
Leong, D. P., McMurray, J. J. V., Joseph, P. G., & Yusuf, S. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.04.068 · Cited by 40
Self-citation
Antisense oligonucleotides for the treatment of cardiomyopathy in Duchenne muscular dystrophy.
Nguyen, Q., & Yokota, T. (2019) · Europe PMC (PubMed Central) · Cited by 39
Variable Impact of Combining Fatal and Nonfatal End Points in Heart Failure Trials
Skali, H., Pfeffer, M. A., Lubsen, J. C., & Solomon, S. D. (2006) · Circulation · doi:10.1161/circulationaha.106.620039 · Cited by 39
Self-citation
Renin-Angiotensin System Modulation: The Weight of Evidence
Brown, B. H., & Hall, A. S. (2005) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2005.06.002 · Cited by 40
The Epidemiology and Pathophysiology of Heart Failure
Rathi, S., & DEEDWANIA, P. C. (2012) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.07.011 · Cited by 41
Review: The therapeutic role of RAS blockade in chronic heart failure
Werner, C. M., & Böhm, M. (2008) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944708091777 · Cited by 39
Chronic heart failure: an overview of conventional treatment versus novel approaches
Landmesser, U., & Drexler, H. (2005) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0371 · Cited by 39
Heart failure: an historical perspective
Ferrari, R., Balla, C., & Fucili, A. (2016) · European Heart Journal Supplements · doi:10.1093/eurheartj/suw042 · Cited by 39
Contemporary Drug Development in Heart Failure: Call for Hemodynamically Neutral Therapies
Vaduganathan, M., Butler, J., Pitt, B., & Gheorghiade, M. (2015) · Circulation: Heart Failure · doi:10.1161/circheartfailure.115.002271 · Cited by 38
Renal Dysfunction in Heart Failure
Cole, R., Masoumi, A., Triposkiadis, F. K., Giamouzis, G., Georgiopoulou, V. V., Kalogeropoulos, A. P., & Butler, J. (2012) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.07.005 · Cited by 38
Unique “delta lock” structure of telmisartan is involved in its strongest binding affinity to angiotensin II type 1 receptor
Ohno, K., Amano, Y., Kakuta, H., Niimi, T., Takakura, S., Orita, M., Miyata, K., Sakashita, H., Takeuchi, M., Komuro, I., et al. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.11.139 · Cited by 38
Unbreakable? An analysis of the fragility of randomized trials that support diabetes treatment guidelines
Kruse, B. C., & Vassar, M. B. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.10.007 · Cited by 38
Evaluation of a guideline directed medical therapy titration program in patients with heart failure with reduced ejection fraction
Balakumaran, K., Patil, A., Marsh, S. P., Ingrassia, J. J., Kuo, C., Jacoby, D. L., Arora, S., & Soucier, R. J. (2018) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2018.10.003 · Cited by 38
Left ventricular diastolic dysfunction of the cardiac surgery patient; a point of view for the cardiac surgeon and cardio-anesthesiologist
Apostolakis, E. E., Baikoussis, N. G., Parissis, H., Siminelakis, S. N., & Papadopoulos, G. S. (2009) · Journal of Cardiothoracic Surgery · doi:10.1186/1749-8090-4-67 · Cited by 38
2007 Guidelines for the Management of Arterial Hypertension The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European
Mancia, G., Dominiczak, A. F., Fagard, R. H., Heagerty, A. M., Kjeldsen, S. E., Laurent, S., Schmieder, R. E., Vahanian, A. S., Camm, A. J., Dean, V., et al. (2007) · Cited by 38
Containing the Cost of Heart Failure Management
Soundarraj, D., Singh, V., Satija, V., & Thakur, R. K. (2016) · Heart Failure Clinics · doi:10.1016/j.hfc.2016.07.002 · Cited by 38
Cardiovascular Drug Therapy in Elderly Patients
Mangoni, A. A. (2005) · Drugs & Aging · doi:10.2165/00002512-200522110-00003 · Cited by 38
Therapeutic effects of angiotensin II type 1 receptor blocker at an advanced stage of hypertensive diastolic heart failure
Nishio, M., Sakata, Y., Mano, T., Yoshida, J., Ohtani, T., Takeda, Y., Miwa, T., Masuyama, T., Yamamoto, K., & Hori, M. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e328010d635 · Cited by 38
The four pillars of HFrEF therapy: is it time to treat heart failure regardless of ejection fraction?
Docherty, K. F., Bayés‐Genís, A., Butler, J., Coats, A. J. S., Drazner, M. H., Joyce, E., & Lam, C. S. P. (2022) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suac113 · Cited by 40
Sex-related similarities and differences in responses to heart failure therapies
Chyou, J. Y., Qin, H., Butler, J., Voors, A. A., & Lam, C. S. P. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-00996-1 · Cited by 39
Falling Cardiovascular Mortality in Heart Failure With Reduced Ejection Fraction and Implications for Clinical Trials
Rush, C. J., Campbell, R. T., Jhund, P. S., Connolly, E. C., Preiss, D., Gardner, R. S., Petrie, M. C., & McMurray, J. J. V. (2015) · JACC Heart Failure · doi:10.1016/j.jchf.2015.03.013 · Cited by 37
Self-citation
Angiotensin-converting Enzyme Inhibitors and Outcomes in Heart Failure and Preserved Ejection Fraction
Mujib, M. U., Patel, K., Fonarow, G. C., Kitzman, D. W., Zhang, Y., Aban, I., Ekundayo, O. J., Love, T. E., Kilgore, M. L., Allman, R. M., et al. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2013.01.004 · Cited by 37
A Practical Guide for the Treatment of Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF)
Reed, B. N., & Sueta, C. A. (2014) · Current Cardiology Reviews · doi:10.2174/1574884708666131117125508 · Cited by 37
Inverse agonism: the classic concept of GPCRs revisited [Review]
Sato, J., Makita, N., & Iiri, T. (2016) · Endocrine Journal · doi:10.1507/endocrj.ej16-0084 · Cited by 38
Long-term management of end-stage heart failure
Habal, M. V., & Garan, A. R. (2017) · Best practice & research. Clinical anaesthesiology · doi:10.1016/j.bpa.2017.07.003 · Cited by 40
Heart Failure With Mid-range Ejection Fraction
Srivastava, P. K., Hsu, J. J., Ziaeian, B., & Fonarow, G. C. (2020) · Current Heart Failure Reports · doi:10.1007/s11897-019-00451-0 · Cited by 38
Effect of the Sodium-Glucose Cotransporter 2 Inhibitor Canagliflozin for Heart Failure With Preserved Ejection Fraction in Patients With Type 2 Diabetes
Ueda, T., Kasama, S., Yamamoto, M., Nakano, T., Ueshima, K., Morikawa, Y., Kawata, H., Yoshihisa, A., Nakayama, M., Komatsu, S., et al. (2021) · Circulation Reports · doi:10.1253/circrep.cr-21-0030 · Cited by 38
Management of heart failure with reduced ejection fraction
Haydock, P., & Flett, A. S. (2022) · Heart · doi:10.1136/heartjnl-2020-318811 · Cited by 37
Exploring the cardiac ECM during fibrosis: A new era with next-gen proteomics
Sarohi, V., Chakraborty, S., & Basak, T. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1030226 · Cited by 42
Effects of Candesartan on Mortality and Morbidity in Patients With Chronic Heart Failure: The CHARM‐Overall Programme
Kantipudi, S., & Khasnis, A. A. (2004) · Congestive Heart Failure · doi:10.1111/j.1527-5299.2004.02799.x · Cited by 37
VALIANT (VALsartan In Acute myocardial iNfarcTion) trial
Maggioni, A. P., & Fabbri, G. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.3.507 · Cited by 37
Diastolic heart failure
GARY, R. A., & Davis, L. L. (2008) · Heart & Lung · doi:10.1016/j.hrtlng.2007.12.002 · Cited by 38
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) Developed in Collaboration With the American College of Chest Physicians and the International Society for Heart and Lung Transplantation
Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M. L., Konstam, M. A., MANCINI, D. M., Michl, K., et al. (2005) · Cited by 37
Efficacy of Angiotensin Receptor Blockers in Cardiovascular Disease
Maggioni, A. P. (2006) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-006-9799-9 · Cited by 38
Effects of Statin Therapy on the Development and Progression of Heart Failure: Mechanisms and Clinical Trials
Khush, K. K., & Waters, D. D. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.05.003 · Cited by 37
Spironolactone Use in Heart Failure Patients With End‐Stage Renal Disease on Hemodialysis: Is It Safe?
Chua, D., Lo, A., & Lo, C. (2010) · Clinical Cardiology · doi:10.1002/clc.20838 · Cited by 36
Stretch-induced regulation of angiotensinogen gene expression in cardiac myocytes and fibroblasts: Opposing roles of JNK1/2 and p38α MAP kinases
Lal, H., Verma, S. K., Golden, H. B., Foster, D. M., Smith, M., & Dostal, D. E. (2008) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2008.09.121 · Cited by 36
Serum Blood Urea Nitrogen and Plasma Brain Natriuretic Peptide and Low Diastolic Blood Pressure Predict Cardiovascular Morbidity and Mortality Following Discharge in Acute Decompensated Heart Failure Patients
Chen, C., Yoshida, A., Asakura, M., Hasegawa, T., Takahama, H., Amaki, M., Funada, A., Asanuma, H., Yokoyama, H., Kim, J., et al. (2012) · Circulation Journal · doi:10.1253/circj.cj-12-0040 · Cited by 36
Comparison of losartan and captopril on heart failure–related outcomes and symptoms from the losartan heart failure survival study (ELITE II)
Konstam, M. A., Neaton, J. D., Poole-Wilson, P. A., Pitt, B., Segal, R., Sharma, D., Dasbach, E. J., Carides, G. W., Dickstein, K., Riegger, G. A. J., et al. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.10.035 · Cited by 36
The role of the AT1 angiotensin receptor in cardiac hypertrophy: angiotensin II receptor or stretch sensor?
Hunyady, L., & Turu, G. (2004) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2004.09.003 · Cited by 36
Review: From Hypertension to Heart Failure — Are There Better Primary Prevention Strategies?
Meredith, P., & Östergren, J. (2006) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.3317/jraas.2006.012 · Cited by 36
Self-citation
Clinical Trials Update from the American Heart Association Meeting: Ω-3 Fatty Acids and Arrhythmia Risk in Patients with an Implantable Defibrillator, ACTIV in CHF, VALIANT, the Hanover autologous bone marrow transplantation study, SPORTIF V, ORBIT and PAD and DEFINITE
Cleland, J. G. F., Freemantle, N., Kaye, G., Nasir, M., Velavan, P., Lalukota, K., Mudawi, T. O., Shelton, R. J., Clark, A. L., & Coletta, A. P. (2004) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2003.12.002 · Cited by 36
Digital solutions to optimize guideline-directed medical therapy prescription rates in patients with heart failure: a clinical consensus statement from the ESC Working Group on e-Cardiology, the Heart Failure Association of the European Society of Cardiology, the Association of Cardiovascular Nursing & Allied Professions of the European Society of Cardiology, the ESC Digital Health Committee, the ESC Council of Cardio-Oncology, and the ESC Patient Forum
Schuuring, M. J., Treskes, R. W., Castiello, T., Jensen, M. T., Casado-Arroyo, R., Neubeck, L., Lyon, A. R., Keser, N., Rucinski, M., Marketou, M. E., et al. (2024) · European Heart Journal - Digital Health · doi:10.1093/ehjdh/ztae064 · Cited by 41
Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin-Receptor Blockers (ARBs) in Patients at High Risk of Cardiovascular Events: A Meta-Analysis of 10 Randomised Placebo-Controlled Trials
Ong, H. T., Ong, L. M., & Ho, J. J. (2013) · ISRN Cardiology · doi:10.1155/2013/478597 · Cited by 37
ESC guidelines adherence is associated with improved survival in patients from the Norwegian Heart Failure Registry
Blois, J. D., Fagerland, M. W., Grundtvig, M., Semb, A. G., Gullestad, L. L., Westheim, A. S., Hole, T., Atar, D., & Agewall, S. (2015) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvu010 · Cited by 35
Improving medication titration in heart failure by embedding a structured medication titration plan
Hickey, A., Suna, J. M., Marquart, L., Denaro, C. P., Javorsky, G., Munns, A., Mudge, A., & Atherton, J. J. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.09.001 · Cited by 35
Patient Factors Associated with Titration of Medical Therapy in Patients with Heart Failure with Reduced Ejection Fraction: Data from the QUALIFY International Registry
Cowie, M., Schöpe, J., Wagenpfeil, S., Tavazzi, L., Böhm, M., Ponikowski, P. P., Anker, S. D., Filippatos, G. S., Michel Komajda, N., & QUALIFY Investigators (2021) · ESC Heart Failure · doi:10.1002/ehf2.13237 · Cited by 35
Efficacy and Tolerability of Adding an Angiotensin Receptor Blocker in Patients with Heart Failure Already Receiving an Angiotensin-Converting Inhibitor Plus Aldosterone Antagonist, With or Without a Beta Blocker. Findings from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM)-Added Trial
Weir, R. A. P., McMurray, J. J. V., Puu, M., Solomon, S. D., Olofsson, B., Granger, C. B., Yusuf, S., Michelson, E. L., Swedberg, K. B., Pfeffer, M. A., et al. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2007.12.006 · Cited by 35
Self-citation
Ranolazine Preserves and Improves Left Ventricular Ejection Fraction and Autonomic Measures When Added to Guideline-Driven Therapy in Chronic Heart Failure
Murray, G. L., & Colombo, J. (2014) · Heart International · doi:10.5301/heartint.5000219 · Cited by 35
Chronic Heart Failure, Selected Risk Factors and Co-Morbidities Among Adults Treated for Hypertension in a Cardiac Referral Hospital in Cameroon
Dzudié, A., Kengne, A. P., Mbahé, S., Ménanga, A., Kenfack, M., & Kingué, S. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2008.02.009 · Cited by 35
Circulatory therapeutics: use of antihypertensive agents and their effects on the vasculature
Schiffrin, E. L. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01056.x · Cited by 35
Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP
Pu, Q., Brassard, P., Javeshghani, D., Iglarz, M., Webb, R. L., Amiri, F., & Schiffrin, E. L. (2008) · Journal of Hypertension · doi:10.1097/hjh.0b013e3282f16aaf · Cited by 38
Add-on Amlodipine Improves Arterial Function and Structure in Hypertensive Patients Treated With an Angiotensin Receptor Blocker
Ichihara, A., Kaneshiro, Y., Sakoda, M., Takemitsu, T. Y., & Itoh, H. (2007) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e31803104e5 · Cited by 35

Authors: McMurray, J. J., Östergren, J., Swedberg, K., Granger, C. B., Held, P., Michelson, E. L., Olofsson, B., Yusuf, S., & Pfeffer, M. A.
Affiliations: University of Glasgow (GB)
Karolinska University Hospital (SE)
Sahlgrenska University Hospital (SE)
Duke Medical Center (US)
AstraZeneca (Sweden) (SE)
AstraZeneca (United States) (US)
Hamilton Health Sciences (CA)
Brigham and Women's Hospital (US)
Corresponding author: McMurray, John JV
ORCID: McMurray, John JV
Östergren, Jan
Swedberg, Karl
Granger, Christopher B
Yusuf, Salim
Pfeffer, Marc A
Venue: The Lancet
Publisher: Elsevier BV
Published: 2003-09
Volume: 362
Issue: 9386
Pages: 767-771
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(03)14283-3
OpenAlex: W2098780362
Cited by: 2,604
References: 38
Citations by year: 2026: 8 · 2025: 15 · 2024: 46 · 2023: 52 · 2022: 58 · 2021: 60 · 2020: 98 · 2019: 82 · 2018: 66 · 2017: 103 · 2016: 108 · 2015: 118 · 2014: 122 · 2013: 126 · 2012: 153
FWCI: 122.65
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
Funders: AstraZeneca
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
Keywords: candesartan, chronic heart failure, reduced left ventricular ejection fraction, angiotensin receptor blockers, ACE inhibitors, combination therapy, cardiovascular mortality, beta-blockers, spironolactone
MeSH terms: Adolescent, Adult, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Benzimidazoles, Biphenyl Compounds, Cardiac Output, Low, Cardiovascular Diseases, Drug Administration Schedule, Drug Therapy, Combination, Female, Follow-Up Studies, Heart Failure, Hospitalization, Humans, Male, Placebos, Tetrazoles, Comorbidity, Treatment Outcome, Ventricular Dysfunction, Left, Angiotensin Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks